[Indications for calcium channel antagonist therapy according to the latest large clinical trials].
Kosicka
Teresa
T
Katedra i Klinika Nadciśnienia Tetniczego, Chorób Naczyń i Chorób Wewnetrznych AM im. Karola Marcinkowskiego w Poznaniu.
Kara-Perz
Hanna
H
Głuszek
Jerzy
J
Perz
Stanisław
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D015201:Meta-Analysis as Topic; D017202:Myocardial Ischemia / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine